Philogen SpA (PHIL.MI) stock: key figures, P/E, revenue and dividend
Health Care · Italy · ISIN IT0005373789
Philogen SpA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 73.00 m EUR | 314.00 m EUR |
| Gross profit | 54.00 m EUR | 271.00 m EUR |
| EBIT | 37.00 m EUR | 251.00 m EUR |
| Net income | 45.00 m EUR | 229.00 m EUR |
| Diluted EPS – continuing operations | 1.12 EUR | 5.67 EUR |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Philogen SpA
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment of glioblastoma; Darleukin which is in Phase II clinical trial for the treatment of non-small cell lung cancer; Dekavil which is in Phase II clinical trial for the treatment of chronic inflammatory disorders; and Dodekin which is in Phase I clinical trial for the treatment of various solid tumors. It is also involved in the development of small molecule products, including OncoFAP which is in Phase I clinical trial for the treatment of solid tumors; OncoACP3 which is in Phase I clinical trial for the treatment of prostate cancer; and OncoCAIX which is in Phase 1 trial for the treatment of renal cell carcinoma and other hypoxic tumors. The company was founded in 1996 and is headquartered in Sovicille, Italy.
More stocks
- Galliford Try Holdings PLC (GFRD.L)
- Qingdao NovelBeam Technology Co. Ltd. A (688677.SS)
- Chengdu Spaceon Electronics Co Ltd Class A (002935.SZ)
- Nippon Paper Industries Co Ltd (3863.T)
- Formosa Taffeta Co Ltd (1434.TW)
- Aktia Bank Abp (AKTIA.HE)
- B2 Impact ASA (B2I.OL)
- Quechen Silicon Chemical Co. Ltd. (605183.SS)
- Daishin Securities Co Ltd Pref (003545.KS)
- Corporación Interamericana de Entretenimiento S.A.B. de C.V (CIEB.MX)
- Diversified Energy Co (DEC)
- China High-Speed Railway Technology (000008.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.